ICUI ICU MEDICAL INC/DE

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0000883984
AI RATING
HOLD
68% Confidence

Investment Thesis

ICU Medical shows explosive revenue and net income growth, but fundamental profitability is severely compressed with a dangerous interest coverage ratio of 0.8x, indicating operating income cannot service debt. The company generates positive free cash flow and maintains strong liquidity, but exceptionally low returns on capital (ROE 1.4%, ROA 0.8%) and 2.6% operating margins suggest growth has outpaced operational efficiency and financial health remains fragile until these metrics improve.

Strengths

  • + Exceptional revenue growth of +2787% YoY with net income doubling
  • + Strong liquidity position with 2.34x current ratio and $288.3M in cash
  • + Positive free cash flow generation of $27.6M despite operational pressures
  • + Reasonable gross margin of 38.9% provides pricing power in medical devices sector

Risks

  • ! Critical: Interest coverage ratio of 0.8x indicates operating income cannot cover interest expenses
  • ! Severely compressed operating margins of 2.6% with high operating expense burden despite 38.9% gross margin
  • ! Abnormally high revenue growth (+2787%) likely acquisition-driven, not organic—sustainability questionable
  • ! Alarming returns on capital: ROE 1.4% and ROA 0.8% indicate poor capital efficiency and value creation
  • ! Only $13.6M operating income on $530.2M revenue raises questions about cost structure and integration

Key Metrics to Watch

Financial Metrics

Revenue
530.2M
Net Income
30.1M
EPS (Diluted)
$1.20
Free Cash Flow
27.6M
Total Assets
4.0B
Cash
288.3M

Profitability Ratios

Gross Margin 38.9%
Operating Margin 2.6%
Net Margin 5.7%
ROE 1.4%
ROA 0.8%
FCF Margin 5.2%

Balance Sheet & Liquidity

Current Ratio
2.34x
Quick Ratio
1.17x
Debt/Equity
0.60x
Debt/Assets
0.0%
Interest Coverage
0.82x
Long-term Debt
1.3B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T11:10:10.066877 | Data as of: 2026-03-31 | Powered by Claude AI